

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hiroaki ITO et al.

Title: A PREVENTIVE OR
THERAPEUTIC AGENT FOR
INFLAMMATORY BOWEL
DISEASE COMPRISING IL-6
ANTAGONIST AS AN ACTIVE
INGREDIENT

Appl. No.: 10/677,227

Filing Date: 10/3/2003

Examiner: Prema Maria MERTZ

Art Unit: 1646

Confirmation: 8597

Number:

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of a document known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present

application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to update or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed document is being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEES

Fees in the amount of \$180.00 in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c) are being paid by credit card via EFS-Web.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit

card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.


Respectfully submitted,

Date June 4, 2007

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

HCW/SBM/ARSC:kdm

Attachment: Form PTO/SB/08


By Stephen B. Macbius, Esq.


Stephen B. Macbius
Attorney for Applicant
Registration No. 35,264

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449-PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/677,227
Date Submitted: June 1, 2007		Filing Date	10/3/2003
(use as many sheets as necessary)		First Named Inventor	Hirosaki ITO
Sheet	1	of	1
		Attorney Docket Number	053488-0386

U.S. PATENT DOCUMENTS

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document Serial Number/Kind Code* or Issue Date	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Column, Lines Where Relevant Passages or Relevant Figures Appear
--------------------	-----------------------	---	--	--	---

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.*	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, where Relevant Passages or Relevant Figures Appear	Page

NON-PATENT LITERATURE DOCUMENTS

Examiner initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
		HARRISON, Paul, et. al., Inhibition of the acute-phase response in vivo by anti-gp130 monoclonal antibodies, British Journal of Haematology, 1995, pp. 443-451, Vol. 95, Blackwell Science Ltd., Oklahoma City, Oklahoma, USA.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Examiner, record of reference communication, whenever an issue occurs as to correspondence with USPTO. 8 Date and signature block is part of communication and not considered. Include copy of this Form with each communication to applicants. 1 Applicant's unique station designation (number/initials); 2 Date Marks Dates of USPTO Patent Documents at www.uspto.gov or USPTO ECR; 3 Exam Office that issued the document, by the two-letter code (WIPO Standard ST 3); 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the series number of the patent document; 5 Name of document by the appropriate symbols as indicated on the document under WIPO Standard ST 18 if possible; 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.87 and 1.88. The information is required to obtain or retain a benefit by the public, which is to be (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.